The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

51 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the usefulness of plasma 1,5-anhydro-D-glucitol (1,5-AG) as a novel surrogate marker of hypoglycemia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus

NCT01161797

Type 2 Diabetes Mellitus

COMPLETED

1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin Ratio as a Potential Biomarker for Islet β-cell Function and Insulin Resistance Among Patients With Type 2 Diabetes Mellitus

NCT04869605

Diabetes Mellitus

UNKNOWN

Glucose Control Using 1,5-AG Testing

NCT03765164

Diabetes

COMPLETED NA

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

NCT06046833

Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Gastroparesis With Diabetes Mellitus

RECRUITING NA

The Management of Glucose Control and Hypoglycemic Prevention Using Continuous Glucose Monitoring System in Patients With Type 1 Diabetes

NCT04684030

Type 1 Diabetes

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We enrolled well controlled diabetes patients who had hypoglycemic event at least one time more. All patients assess the risk of severe hypoglycemia and hypoglycemic unawareness using hypoglycemic awareness questionnaires (HYPO score). The patients who are treated with insulin agent were inserted sensor of continuous glucose monitoring systems under the skin during three days. We were analysed the correlation between 1,5-anhydro-D-glucitol and HYPO score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus With Hypoglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients attending outpatients of department of endocrinology and metabolism, seoul national university hospital .(HbA1C \<8%)
* The patients who treated with insulin or sulfonylureas at least 3month period
* In case fo sulfonylurea user, HbA1c was restricted under 8%
* The patients who had hypoglycemic event at least 3 months
* who has can be survey questionnaire
* who can insert continuous glucose monitoring system

Exclusion Criteria

* renal dysfunction patients
* hepatic dysfunction patients
* who has any kind of diseases, operations, medical treatments that can affect glucose levels

Eligible Sex

ALL

Accepts Healthy Volunteers

No